Life science start-ups are invited to apply for the opportunity to win access to the Babraham Research Campus bio-incubator facilities, plus an extended programme of support and mentoring
Babraham 6th March 2019: Accelerate@Babraham supports the development of early-stage science concepts and the creation of new life science companies through access to equipped communal laboratories on short-term agreements, as well as guidance from mentors and introductions to investors. The annual Accelerate@Babraham competition gives up to five ventures the opportunity to win access to these facilities,…
Inivata Receives Medicare Final Coverage Decision for InVisionFirst-Lung Liquid Biopsy Test in
Advanced Non-Small Cell Lung Cancer
Final Coverage Supports the Use of InVisionFirst-Lung for Aiding in the Management of Patients with Advanced NSCLC
Research Triangle Park, NC and Cambridge, UK, March 5, 2019 -- Inivata, a leader in liquid biopsy, today announces that Palmetto GBA, a Medicare Administrative Contractor recognized for its molecular diagnostic technology assessment experience through its assessment group, MolDx, has issued its final Coverage Determination for InVisionFirst™-Lung…
Research Triangle Park, NC and Cambridge, UK, March 5, 2019 -- Inivata, a leader in liquid biopsy, today announces that Palmetto GBA, a Medicare Administrative Contractor recognized for its molecular diagnostic technology assessment experience through its assessment group, MolDx, has issued its final Coverage Determination for InVisionFirst™-Lung Liquid Biopsy test, a blood-based circulating tumor DNA (ctDNA) test for the detection of genomic alterations in the most commonly mutated genes in advanced Non-Small Cell Lung Cancer (NSCLC).
This policy, which becomes effective April 8, 2019,…
Cambridge, UK, 26 February: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property (IP) relating to methods for predicting autoimmune disease risk. This follows successful grants across the company’s first family of IP in the UK and Europe in October 2018 and Canada in January this year.
The focus of the US patent is on the biological mechanism of the test, which…
Cambridge UK: 25 February 2019 - Lonza Biologics becomes the latest One Nucleus Partner. The Partner Program is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.Sarah Holland, Global Head of Licensing at Lonza commented ‘Lonza has been a member of the One Nucleus ecosystem for a number of years. We are delighted to strengthen our relationship further by becoming a One Nucleus partner. We are committed to supporting innovation and see the building of strong relationships with biotechnology companies and research institutes as a key part of our…
18 February 2019 – Oxford: Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.
Under the agreement, Sphere Fluidics will act as the lead partner, looking to utilise its extensive expertise in microfluidic systems to produce new products designed to meet the requirements of multiplexed gene editing workflows.
Oxford Genetics and the University of Edinburgh will provide input into industrial and application specific requirements, both in…
Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products for patient benefit, has announced a key appointment in support of its continued growth plans.
Dr Sabine Rühle joins Boyds as Senior Associate of Regulatory Affairs and will be based at Boyds’ Cambridge offices, which opened last year.
A member of the Organisation of Professionals in Regulatory Affairs (MTOPRA), Sabine joins from Pharmaceutical Product Development, where she was Senior Regulatory Affairs Specialist and coordinated global CTA submissions for a variety of products and…
PRINCETON, NJ – Feb. 21, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360. D360 v19.1 expands the platform’s capabilities for biologists and biologics scientists, deepens support for small molecule chemistry, and provides workflow enhancements based on community feedback. This latest version of D360 takes its name from its calendar release date; this is the first new release in 2019.
The role of drug discovery…
Cambridge, UK, and Shanghai, China, February 20 2019: Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji Hospital, today announced a collaboration to conduct a clinical trial into the early detection of lung cancer with support from the Li Ka Shing Foundation.
Recognizing the escalating incidence of lung cancer in China, Owlstone Medical and Renji Hospital have a mutual interest in developing and making accessible diagnostics for the early detection of disease, which can result in the…
Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products and devices for patient benefit, has established an office facility at Alderley Park as part of continued growth plans.
Boyds, which has headquarters in Crewe, and has recently expanded into new premises in Cambridge and Dublin, now employs 20 members of staff.
Alderley Park, a development by Bruntwood SciTech, is home to the internationally-recognised Mereside bioscience campus which offers more than 1m sq ft of high specification lab space, a range of scientific services and the Alderley…